STEM Times of Connecticut
SEE OTHER BRANDS

Your best source on science and technology news from Connecticut

STEM Times of Connecticut: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times of Connecticut.

Press releases published on May 8, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell …

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort …

Inspired Reports First Quarter 2025 Results

Inspired Reports First Quarter 2025 Results

First Quarter Revenue of $60.4 million, driven primarily by record Interactive revenue, up 49% year-over-year First Quarter Net Loss of $0.1 million and Adjusted Net Income of $3.8 million First Quarter Adjusted EBITDA of $18.4 million, up 19% from last …

Purple Garden Empowers Users With Trusted Psychic Guidance

Purple Garden Empowers Users With Trusted Psychic Guidance

San Francisco, CA, May 08, 2025 (GLOBE NEWSWIRE) -- Purple Garden is a popular online platform that offers psychic readings to customers anytime and anywhere.  The platform has been operating for several years and is considered an industry leader in online …

Lucinity Featured in Chartis Research FinCrime and Compliance 50 Ranking for 2025

Lucinity Featured in Chartis Research FinCrime and Compliance 50 Ranking for 2025

REYKJAVIK, Iceland, May 08, 2025 (GLOBE NEWSWIRE) -- Lucinity has been listed among the top 50 Financial Crime and Compliance (FCC) companies in the 2025 FCC50 ranking by Chartis Research. This recognition reflects Lucinity’s continued ability to deliver …

Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares

Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares

ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha …

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, …

HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and …

Seamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih

Seamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih

Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics, today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an experienced drug developer and physician with a track record of …

ProQR Announces First Quarter 2025 Operating and Financial Results

ProQR Announces First Quarter 2025 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases  Strengthened leadership with appointments of Chief Financial Officer …

Kaltura Announces Financial Results for First Quarter 2025

Kaltura Announces Financial Results for First Quarter 2025

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Kaltura, Inc. (“Kaltura” or the “Company”), the video experience cloud, today announced financial results for the first quarter ended March 31, 2025, as well as outlook for the second quarter and full year 2025. " …

Fred Ball Joins Axonius Board of Directors to Drive Financial and Global Expansion

Fred Ball Joins Axonius Board of Directors to Drive Financial and Global Expansion

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Axonius, the leader in cyber asset management that delivers visibility and actionability across all digital assets, today announced the appointment of Fred Ball to its Board of Directors. Ball, a veteran finance …

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical …

BigCommerce Announces First Quarter 2025 Financial Results

BigCommerce Announces First Quarter 2025 Financial Results

AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- BigCommerce Holdings, Inc. (“BigCommerce” or the “Company”) (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands, retailers, manufacturers and …

Apyx Medical Corporation Reports First Quarter 2025 Financial Results

Apyx Medical Corporation Reports First Quarter 2025 Financial Results

Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year Preparing for a planned launch of the AYON™ Body …

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in …

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability …

Aduro Clean Technologies and Cleanfarms Sign Memorandum of Understanding to Collaborate on Development of Commercial Pathway for Challenging Agricultural Plastics

Aduro Clean Technologies and Cleanfarms Sign Memorandum of Understanding to Collaborate on Development of Commercial Pathway for Challenging Agricultural Plastics

LONDON, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service